We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Harnessing the Power of ddPCR to Advance Precision Oncology

Harnessing the Power of ddPCR to Advance Precision Oncology

Liquid biopsies and the advent of blood-based diagnostics have emerged in recent years as promising alternatives and complements to tissue-based genomic and proteomic assays. Biodesix, a global leader in molecular diagnostics and assay design/development, leverages cutting-edge technology, including droplet digital PCR (ddPCR), to advance translational and clinical oncology research and to assist biopharma companies in delivering new, targeted, life-saving therapies to patients. 

This presentation provides a comprehensive exploration of new blood-based diagnostics, including the development of a microsatellite instability (MSI) test on the ddPCR platform and the dynamic monitoring capabilities of ddPCR using circulating tumor DNA (ctDNA).

During this talk we discuss:

  • Biodesix assays and their broad applications in cancer research and therapeutic development
  • Dynamic monitoring of treatment response using ddPCR detection of ctDNA with insights from a recent biopharma collaboration
Trevor Pitcher, PhD
Trevor Pitcher, PhD
Senior Director, Biodesix Inc.